Vanishing White Matter Disease Trial Update

Calico has announced that ‘the first participant has been dosed in a Phase 1b clinical trial, (study M23-523; NCT05757141), evaluating the investigational eIF2B activator ABBV-CLS-7262 as a potential treatment for Vanishing White Matter (VWM) disease’.

To read the press release: Calico Press Release